Acadia Healthcare (ACHC) Q3 2026 Earnings Call Transcript

Acadia Healthcare reported Q3 2026 revenue of $895.3 million, up 5.1% year over year, and adjusted EBITDA of $176.4 million, up 2%; adjusted EPS fell to $0.60 from $0.72. The company raised full-year 2026 guidance to revenue of $3.44 billion-$3.46 billion, adjusted EBITDA of $615 million-$625 million and adjusted EPS of $1.70-$1.80, its third consecutive guidance increase. Management expects $60 million of incremental adjusted EBITDA in 2027 from facilities opened since the beginning of 2023, while citing New York Medicaid changes as a headwind to same-facility growth.

Analysis

The positive read-through is less about this quarter’s beat than whether ACHC can convert recently added capacity into durable cash earnings. The 2027 cohort target has meaningful execution leverage: management attributes roughly half of the projected $60 million EBITDA increase to reducing startup losses, with the remainder dependent on occupancy and margins at older openings. That makes licensing speed and staffing useful leading indicators, but not proof of profitable demand; the roughly 40% break-even occupancy reference is a key test to monitor facility by facility.

Earnings quality is the main near-term counterweight. Supplemental-payment approvals could add upside, but timing and final amounts are uncertain, and prior out-of-period items complicate the run-rate. Separate core growth from these reimbursements before capitalizing the guidance increase. The New York Medicaid disruption is also not simply a temporary volume dip: replacing a large patient cohort and rebuilding referral flows may take multiple quarters. Continued strength in acute care may obscure weakness in specialty and CTC, while shorter stays and a lower commercial mix could affect revenue quality and operating leverage.

Over 1–3 months, the next guidance update and evidence of referral replacement, denials stabilization, and startup-loss reduction matter more than the headline EBITDA target. Over 6–18 months, lower development capex should improve cash conversion and debt reduction if occupancy ramps; conversely, persistent therapist/social-worker constraints or policy-driven Medicaid losses could undermine that harvest phase. Consensus may over-credit the $60 million as organic growth: a substantial portion is loss normalization, and more than $20 million of potential payment-program EBITDA is unapproved. No valuation or price data are supplied, so avoid assuming the beat is under- or over-priced.

Key Decisions for Investors

• Maintain a modest, catalyst-led long bias in ACHC, but do not chase the earnings reaction. Add only if subsequent disclosures confirm cohort occupancy gains and a path toward startup losses near management’s 2027 expectation.
• Treat Florida and Ohio supplemental payments as contingent upside, not base-case earnings. Track approval timing, recognized revenue versus cash receipts, and reconciliation of out-of-period items before raising the normalized EBITDA estimate.
• Use the next 1–3 months to monitor same-facility patient days excluding the New York disruption, referral replacement in Pennsylvania, and bad debt/denials as a share of revenue. Persistent weakness or a renewed deterioration in denials would invalidate the constructive operating thesis.
• The capex reduction supports a cash-generation thesis only if maintenance needs remain funded and occupancy improves. Reassess if ACHC resumes de novo spending before the existing facility cohort is visibly ramping, or if leverage stops declining despite reported EBITDA growth.